Jim Birchenough
Stock Analyst at Wells Fargo
(2.56)
# 2,206
Out of 4,876 analysts
36
Total ratings
42.86%
Success rate
19.09%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jim Birchenough
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SGMO Sangamo Therapeutics | Maintains: Equal-Weight | $3 → $2 | $0.54 | +269.75% | 2 | Dec 31, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Equal-Weight | $55 → $70 | $47.49 | +47.40% | 3 | Feb 22, 2024 | |
| MEIP MEI Pharma | Downgrades: Equal-Weight | $260 → $40 | $2.70 | +1,381.48% | 4 | Mar 25, 2022 | |
| ZYME Zymeworks | Maintains: Overweight | $56 → $48 | $12.47 | +284.92% | 3 | Feb 9, 2022 | |
| ADAP Adaptimmune Therapeutics | Maintains: Equal-Weight | $6 → $7 | $0.25 | +2,757.14% | 2 | Sep 22, 2021 | |
| FATE Fate Therapeutics | Maintains: Overweight | $84 → $130 | $1.04 | +12,400.00% | 4 | Mar 4, 2021 | |
| PGEN Precigen | Initiates: Overweight | $14 | $1.42 | +885.92% | 1 | Feb 22, 2021 | |
| MRNA Moderna | Maintains: Equal-Weight | $129 → $145 | $27.16 | +433.87% | 2 | Feb 1, 2021 | |
| GILD Gilead Sciences | Maintains: Equal-Weight | $69 → $63 | $110.67 | -43.07% | 5 | Oct 29, 2020 | |
| RNA Avidity Biosciences | Initiates: Overweight | n/a | $29.03 | - | 1 | Jul 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $56 | $13.86 | +304.04% | 3 | Jun 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $734 | $521.00 | +40.88% | 2 | May 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $300 → $180 | $4.35 | +4,037.93% | 1 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $33 | $6.44 | +412.42% | 3 | Jun 28, 2018 |
Sangamo Therapeutics
Dec 31, 2024
Maintains: Equal-Weight
Price Target: $3 → $2
Current: $0.54
Upside: +269.75%
CRISPR Therapeutics AG
Feb 22, 2024
Maintains: Equal-Weight
Price Target: $55 → $70
Current: $47.49
Upside: +47.40%
MEI Pharma
Mar 25, 2022
Downgrades: Equal-Weight
Price Target: $260 → $40
Current: $2.70
Upside: +1,381.48%
Zymeworks
Feb 9, 2022
Maintains: Overweight
Price Target: $56 → $48
Current: $12.47
Upside: +284.92%
Adaptimmune Therapeutics
Sep 22, 2021
Maintains: Equal-Weight
Price Target: $6 → $7
Current: $0.25
Upside: +2,757.14%
Fate Therapeutics
Mar 4, 2021
Maintains: Overweight
Price Target: $84 → $130
Current: $1.04
Upside: +12,400.00%
Precigen
Feb 22, 2021
Initiates: Overweight
Price Target: $14
Current: $1.42
Upside: +885.92%
Moderna
Feb 1, 2021
Maintains: Equal-Weight
Price Target: $129 → $145
Current: $27.16
Upside: +433.87%
Gilead Sciences
Oct 29, 2020
Maintains: Equal-Weight
Price Target: $69 → $63
Current: $110.67
Upside: -43.07%
Avidity Biosciences
Jul 7, 2020
Initiates: Overweight
Price Target: n/a
Current: $29.03
Upside: -
Jun 25, 2020
Downgrades: Equal-Weight
Price Target: $56
Current: $13.86
Upside: +304.04%
May 26, 2020
Upgrades: Overweight
Price Target: $734
Current: $521.00
Upside: +40.88%
Mar 13, 2020
Maintains: Overweight
Price Target: $300 → $180
Current: $4.35
Upside: +4,037.93%
Jun 28, 2018
Maintains: Outperform
Price Target: $31 → $33
Current: $6.44
Upside: +412.42%